← All trials
NCT06265532
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 7, 2024
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Feb 20, 2024
- Last posted
- Feb 20, 2024
- Enrollment
- 22
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Cornell UniversityCollaborator
- University of California, San FranciscoSponsor investigator
- University of MichiganCollaborator
- Harvard UniversityCollaborator
- Cornell UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.